Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

When approved, ONS-5010/LYTENAVA™ will be the first and only FDA-approved ophthalmic formulation of bevacizumab supported by standardized manufacturing, FDA-approved labeling, and robust ...

Outlook Therapeutics Resubmits FDA Application for ONS-5010

Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.
Stocktwits on MSN

OTLK stock surges on FDA Lytenava application resubmission after successful appeal

The FDA had refused to approve the drug in December, but Outlook appealed the decision. ・The resubmission follows the agency's conclusion that no additional trials for Lytenava are required, as ...

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of ...
The National Law Review

Outlook Therapeutics Announces New Employment Inducement Grants

ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...
The National Law Review

Outlook Therapeutics Announces Proposed Public Offering

ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE)-- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...
Seeking Alpha

Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026 Additional European launches expected in 2026 Type A meeting request ...
Nasdaq

Outlook Therapeutics reports FY24 EPS ($4.06) vs. ($4.72) last year

“Over the course of the past year, our team has continued to execute and progress the development of ONS-5010/LYTENAVA in Europe and the United States. Following the receipt of our first positive ...
The Globe and Mail

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ...

Outlook shares jump following FDA appeal decision for LYTENAVA

Outlook Therapeutics, Inc. OTLK shares are trading higher Tuesday after the company announced that the U.S. Food and Drug ...
Nasdaq

Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations

ISELIN, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of ...